ADVL-0912: A Phase 1/2 Study of PF-02341066, an Oral Small Molecule Inhibitor of Anaplastic Lymphoma Kinase (ALK) and C-Met, in Children with Relapsed/Refractory Solid Tumors and Anaplastic Large Cell Lymphoma

Project: Research project

Project Details

StatusFinished
Effective start/end date11/1/1410/31/17

Funding

  • Children's Hospital of Philadelphia
  • Pfizer Inc.